Ixabepilone
- Generic Name
- Ixabepilone
- Brand Names
- Ixempra
- Drug Type
- Small Molecule
- Chemical Formula
- C27H42N2O5S
- CAS Number
- 219989-84-1
- Unique Ingredient Identifier
- K27005NP0A
- Background
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue ...
- Indication
用于在其他化学治疗均失效后作为治疗晚期乳腺癌的药物。
- Associated Conditions
- Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer
- Associated Therapies
- -
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
- Conditions
- Adult Primary Cholangiocellular CarcinomaAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerCholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderLocalized Extrahepatic Bile Duct CancerLocalized Gallbladder CancerLocalized Resectable Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00023946
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00043095
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- R-Pharm
- Registration Number
- NCT00049244
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00028561
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT00025155
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 57
- Registration Number
- NCT00045708
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.